UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC Boosts Stock Position in Theravance Biopharma, Inc. (NASDAQ:TBPH)

UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC grew its stake in Theravance Biopharma, Inc. (NASDAQ:TBPH - Free Report) by 27.7% in the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 150,039 shares of the biopharmaceutical company's stock after buying an additional 32,534 shares during the period. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC owned approximately 0.31% of Theravance Biopharma worth $1,412,000 at the end of the most recent reporting period.

A number of other institutional investors have also recently made changes to their positions in TBPH. SG Americas Securities LLC increased its position in shares of Theravance Biopharma by 21.1% during the 4th quarter. SG Americas Securities LLC now owns 19,202 shares of the biopharmaceutical company's stock valued at $181,000 after purchasing an additional 3,349 shares during the last quarter. Charles Schwab Investment Management Inc. boosted its stake in Theravance Biopharma by 0.7% in the fourth quarter. Charles Schwab Investment Management Inc. now owns 293,936 shares of the biopharmaceutical company's stock worth $2,766,000 after buying an additional 2,060 shares in the last quarter. Teacher Retirement System of Texas purchased a new position in shares of Theravance Biopharma during the fourth quarter worth approximately $103,000. Magnetar Financial LLC lifted its holdings in shares of Theravance Biopharma by 125.8% in the 4th quarter. Magnetar Financial LLC now owns 27,511 shares of the biopharmaceutical company's stock worth $259,000 after acquiring an additional 15,328 shares during the last quarter. Finally, American Century Companies Inc. grew its holdings in shares of Theravance Biopharma by 11.9% during the 4th quarter. American Century Companies Inc. now owns 77,931 shares of the biopharmaceutical company's stock valued at $733,000 after purchasing an additional 8,289 shares during the last quarter. Institutional investors own 99.10% of the company's stock.

Insiders Place Their Bets

In other news, SVP Rhonda Farnum sold 24,000 shares of the company's stock in a transaction dated Monday, June 2nd. The shares were sold at an average price of $11.00, for a total value of $264,000.00. Following the sale, the senior vice president now directly owns 336,918 shares of the company's stock, valued at $3,706,098. This represents a 6.65% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. 6.90% of the stock is owned by corporate insiders.

Theravance Biopharma Price Performance

NASDAQ:TBPH remained flat at $10.61 during trading hours on Thursday. 310,183 shares of the company traded hands, compared to its average volume of 276,281. The firm has a market cap of $530.51 million, a P/E ratio of -10.50 and a beta of -0.09. The company's 50 day simple moving average is $9.47 and its 200-day simple moving average is $9.42. Theravance Biopharma, Inc. has a twelve month low of $7.44 and a twelve month high of $11.82.

Theravance Biopharma (NASDAQ:TBPH - Get Free Report) last announced its earnings results on Thursday, May 8th. The biopharmaceutical company reported ($0.27) earnings per share for the quarter, missing analysts' consensus estimates of ($0.11) by ($0.16). Theravance Biopharma had a negative net margin of 78.18% and a negative return on equity of 24.79%. The company had revenue of $15.39 million for the quarter, compared to the consensus estimate of $28.08 million. On average, sell-side analysts forecast that Theravance Biopharma, Inc. will post -1.09 EPS for the current fiscal year.

Wall Street Analyst Weigh In

Several brokerages recently weighed in on TBPH. HC Wainwright restated a "buy" rating and set a $15.00 target price on shares of Theravance Biopharma in a report on Tuesday, February 25th. Wall Street Zen raised Theravance Biopharma from a "hold" rating to a "buy" rating in a research note on Wednesday, May 14th. Three research analysts have rated the stock with a hold rating and two have assigned a buy rating to the company. According to data from MarketBeat, Theravance Biopharma currently has an average rating of "Hold" and a consensus price target of $11.33.

Theravance Biopharma Profile

Theravance Biopharma, Inc is a diversified biopharmaceutical company primarily focused on the discovery, development and commercialization of organ-selective medicines. Its purpose is to pioneer a new generation of small molecule drugs designed to better meet patient needs. Its research is focused in the areas of inflammation and immunology. In pursuit of its purpose, Theravance Biopharma applies insights and innovation at each stage of its business and utilizes its internal capabilities and those of partners around the world.